Efficacy outcomes in Black patients from the ARANOTE trial

ARANOTE Subanalysis Results

Key Themes:

• Ten percent of the ARANOTE study population were Black men.
• Radiologic progression-free survival was similar in Black men (HR, 0.51) vs the overall population (HR, 0.54).
• Time to metastatic castrate-resistant prostate cancer showed a comparable response.
• Complete PSA suppression rates showed 3-fold improvement (59.5% vs 18.2%) with darolutamide.

Key Points for Physicians:

• Darolutamide plus ADT shows comparable efficacy in Black men.
• All major efficacy end points demonstrate consistent benefit across racial groups.
• PSA suppression rate was particularly impressive with the addition of darolutamide.

Notable Insights: The consistency of benefit across multiple clinically meaningful end points provides robust evidence supporting darolutamide’s efficacy in Black men.

Clinical Significance: This subanalysis provides race-specific evidence supporting the use of darolutamide in Black men with metastatic hormone-sensitive prostate cancer, addressing an important gap in prostate cancer treatment evidence.